Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Gains from Sales and Divestitures (2024)

Bioregenx (BRGX) has 1 years of Gains from Sales and Divestitures data on record, last reported at $6.1 million in Q4 2024.

  • For Q4 2024, Gains from Sales and Divestitures changed N/A year-over-year to $6.1 million; the TTM value through Dec 2024 reached $6.1 million, changed N/A, while the annual FY2024 figure was $6.1 million, N/A changed from the prior year.
  • Gains from Sales and Divestitures reached $6.1 million in Q4 2024 per BRGX's latest filing, up from $4.0 million in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $6.1 million in Q4 2024 and bottomed at $4.0 million in Q1 2024.